These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36703790)

  • 21. Nuclear receptor coactivator 6 (NCoA6) promotes cell proliferation, migration, and invasion in pancreatic cancer.
    Wang X; Jia Y; Xu X; Hu Y; Fan G; Jing D; Zhang Z; Wang C; Song C; Qin Y; Peng L
    Cancer Med; 2023 Sep; 12(17):18425-18439. PubMed ID: 37553876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MIF/NR3C2 Axis Regulates Glucose Metabolism Reprogramming in Pancreatic Cancer through MAPK-ERK and AP-1 Pathways.
    Yang S; Tang W; Azizian A; Gaedcke J; Ohara Y; Cawley H; Hanna N; Ghadimi BM; Lal T; Sen S; Creighton CJ; Gao J; Putluri N; Ambs S; Hussain SP
    Carcinogenesis; 2024 Apr; ():. PubMed ID: 38629149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.
    Huang C; Xie D; Cui J; Li Q; Gao Y; Xie K
    Clin Cancer Res; 2014 Mar; 20(6):1477-88. PubMed ID: 24452790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.
    Büchler P; Reber HA; Tomlinson JS; Hankinson O; Kallifatidis G; Friess H; Herr I; Hines OJ
    Neoplasia; 2009 Feb; 11(2):196-206. PubMed ID: 19177204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer.
    Sun H; Zhang D; Huang C; Guo Y; Yang Z; Yao N; Dong X; Cheng R; Zhao N; Meng J; Sun B; Hao J
    Cancer Biol Med; 2021 Jun; 18(2):616-30. PubMed ID: 34086429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
    Funamizu N; Hu C; Lacy C; Schetter A; Zhang G; He P; Gaedcke J; Ghadimi MB; Ried T; Yfantis HG; Lee DH; Subleski J; Chan T; Weiss JM; Back TC; Yanaga K; Hanna N; Alexander HR; Maitra A; Hussain SP
    Int J Cancer; 2013 Feb; 132(4):785-94. PubMed ID: 22821831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
    Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
    Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
    Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
    Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway.
    Graham CH; Fitzpatrick TE; McCrae KR
    Blood; 1998 May; 91(9):3300-7. PubMed ID: 9558386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRP1 regulates remodeling of the extracellular matrix by fibroblasts.
    Gaultier A; Hollister M; Reynolds I; Hsieh EH; Gonias SL
    Matrix Biol; 2010 Jan; 29(1):22-30. PubMed ID: 19699300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression.
    Gao C; Li S; Zhao T; Chen J; Ren H; Zhang H; Wang X; Lang M; Liu J; Gao S; Zhao X; Sheng J; Yuan Z; Hao J
    PLoS One; 2015; 10(3):e0121338. PubMed ID: 25799412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mosaic receptor sorLA/LR11 binds components of the plasminogen-activating system and platelet-derived growth factor-BB similarly to LRP1 (low-density lipoprotein receptor-related protein), but mediates slow internalization of bound ligand.
    Gliemann J; Hermey G; Nykjaer A; Petersen CM; Jacobsen C; Andreasen PA
    Biochem J; 2004 Jul; 381(Pt 1):203-12. PubMed ID: 15053742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
    Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
    J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells.
    Tanouchi A; Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Kimura M; Watanabe R; Kohsaki T; Shimizu T; Saito M; Hanazaki K; Saibara T
    J Exp Clin Cancer Res; 2016 Dec; 35(1):190. PubMed ID: 27919290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
    Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
    Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.